Masaaki Yanishi1, Hiroyasu Tsukaguchi2, Yutaka Kimura3, Yuya Koito4, Kenji Yoshida4, Maiko Seo2, Eri Jino4, Motohiko Sugi4, Hidefumi Kinoshita4, Tadashi Matsuda4. 1. Department of Urology and Andrology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan. masaaki.yanishi@gmail.com. 2. 2nd Department of Internal Medicine, Division of Nephrology, Kansai Medical University, Osaka, Japan. 3. Health Science Center, Kansai Medical University, Osaka, Japan. 4. Department of Urology and Andrology, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan.
Abstract
INTRODUCTION: Sarcopenia is an involuntary decline in skeletal muscle mass, strength, and function that normally proceed with aging but may develop faster under some chronic disease conditions. In this study, we compared the physical activity between sarcopenia and non-sarcopenia subgroups in kidney transplant recipients. METHODS: Fifty-eight recipients (42 males and 16 females) were enrolled in this study. Mean age of the recipients was 46.6 ± 12.7 years. Mean duration of dialysis was 2.8 ± 4.0 years. Diagnostic criteria for sarcopenia referred to those of the Asia Working Group for Sarcopenia. The physical activity was assessed using the International Physical Activity Questionnaire, and the intensity of physical activity was expressed in metabolic equivalents (MET). RESULTS: Based on the skeletal muscle mass index (SMI) as well as functional index (HGS, walking speed), the participants were classified into the three subgroups: 12 patients (20.7%) with sarcopenia (Group 1), 25 (43.1%) with presarcopenia (Group 2), and 21 (36.2%) non-sarcopenia (Group 3). Analysis with ANOVA and pairwise comparisons showed that physical activity measured as total MET-min/week was significantly greater in Group 2 (1292 ± 633) than in Group (1484 ± 262). Moreover, physical activity of Group 3 (2461 ± 1339)-min/week was significantly greater than those of Groups 1 and 2. CONCLUSIONS: Our data indicate that physical activity is restricted under presarcopenia and sarcopenia after kidney transplantation. Considering that the recipient age is now increasing, proper management of sarcopenia may become more crucial to improve the kidney survival and lifetime prognosis of the kidney transplant recipients.
INTRODUCTION:Sarcopenia is an involuntary decline in skeletal muscle mass, strength, and function that normally proceed with aging but may develop faster under some chronic disease conditions. In this study, we compared the physical activity between sarcopenia and non-sarcopenia subgroups in kidney transplant recipients. METHODS: Fifty-eight recipients (42 males and 16 females) were enrolled in this study. Mean age of the recipients was 46.6 ± 12.7 years. Mean duration of dialysis was 2.8 ± 4.0 years. Diagnostic criteria for sarcopenia referred to those of the Asia Working Group for Sarcopenia. The physical activity was assessed using the International Physical Activity Questionnaire, and the intensity of physical activity was expressed in metabolic equivalents (MET). RESULTS: Based on the skeletal muscle mass index (SMI) as well as functional index (HGS, walking speed), the participants were classified into the three subgroups: 12 patients (20.7%) with sarcopenia (Group 1), 25 (43.1%) with presarcopenia (Group 2), and 21 (36.2%) non-sarcopenia (Group 3). Analysis with ANOVA and pairwise comparisons showed that physical activity measured as total MET-min/week was significantly greater in Group 2 (1292 ± 633) than in Group (1484 ± 262). Moreover, physical activity of Group 3 (2461 ± 1339)-min/week was significantly greater than those of Groups 1 and 2. CONCLUSIONS: Our data indicate that physical activity is restricted under presarcopenia and sarcopenia after kidney transplantation. Considering that the recipient age is now increasing, proper management of sarcopenia may become more crucial to improve the kidney survival and lifetime prognosis of the kidney transplant recipients.
Authors: Cassianne Robinson-Cohen; Alyson J Littman; Glen E Duncan; Noel S Weiss; Michael C Sachs; John Ruzinski; John Kundzins; Denise Rock; Ian H de Boer; T Alp Ikizler; Jonathan Himmelfarb; Bryan R Kestenbaum Journal: J Am Soc Nephrol Date: 2013-12-12 Impact factor: 10.121
Authors: Baback Roshanravan; Cassianne Robinson-Cohen; Kushang V Patel; Ernest Ayers; Alyson J Littman; Ian H de Boer; T Alp Ikizler; Jonathan Himmelfarb; Leslie I Katzel; Bryan Kestenbaum; Stephen Seliger Journal: J Am Soc Nephrol Date: 2013-04-18 Impact factor: 10.121
Authors: Heitor O Santos; Larissa S Limirio; Aline S Dos Reis; Rafaela Nehme; João Pedro Floriano; Gederson K Gomes; Gustavo D Pimentel; Erick P de Oliveira Journal: Inflammation Date: 2022-06-21 Impact factor: 4.092
Authors: Ilaria Gandolfini; Giuseppe Regolisti; Alberto Bazzocchi; Umberto Maggiore; Alessandra Palmisano; Giovanni Piotti; Enrico Fiaccadori; Alice Sabatino Journal: Front Nutr Date: 2019-11-12